Rojas RA, Toledo AR, Rojas RMS

Language: Spanish
References: 14
Page: 297-301
PDF size: 146.64 Kb.

ABSTRACT

Background: Dengue is an endemic viral disease in Coatzacoalcos, Ver. México. It causes fever, plus severe joint and muscle pain. Its pharmacological treatment is a simple “over-the counter” pain reducing drug, usually paracetamol.
Objective: To assess the correct usage and safety of administrating metamizol to patients with dengue fever (DF) and dengue hemorragic fever (DHF).
Patients and methods: We observed and kept record of 50 DF and DHF cases through out a one year period from January 2005 to December 2005. Each case was diagnosed by clinical findings and specific blood test for detection of anti-dengue IgM and anti-dengue IgG antibodies. All patients were treated with metamizol regardless of thrombocitopenia and leukopenia and hemorragic manifestations. All of the patients were studied by hemograms including thrombocyte and leukocyte counts and urinary test and also aspartate aminotransferase from the beginning to remission.
Results: 4 patients (8%) fulfilled the criteria of DHF; 46 patients had classic dengue fever (92%); 19 cases were male and 31 cases were female. 40 cases (80%) showed a leukocyte count below 5,000 and 40 cases showed thrombocyte count below 100,000; 14 of them (28%) had platelets below 50,000 at the beginning of the study. The AST level was high (2 times above normal) in 38 cases (76%). All patients tolerated metamizol, 32 of them took it 4 to 8 days (64%) and 4 patients with dengue hemorragic fever were given metamizol intravenously. All 50 patients showed excellent clinical response to the drug, there were no collateral reactions.
Conclusion: Metamizol is safe and effective treatment in patients with dengue fever and dengue hemorragic fever and it could be used as first regimen in these patients.

REFERENCES

1. Martínez Torres E. Dengue y dengue hemorrágico: aspectos clínicos. Salud Pública Mex 1995;37(Supl):529-44.

2. Organización Panamericana de la Salud. Dengue y dengue hemorrágico en Las Américas; guías para la prevención y control. Washington, DC: OPS, 2004.

3. Dengue y dengue hemorrágico en Las Americas. Washington, DC: OPS, 1995;pp:11-14.

4. Montesano-Castellanos R, Ruiz Matus C. Vigilancia epidemiológica del dengue en México. Salud Pública Mex 1995;37(Supl):64-76.

5. Halpern LM. Analgesic drugs in the management of pain. Arch Surg 1997;12:880-3.

6. Cortez Diagnostic, Inc. Dengue IgG/IgM. Cat. No. 173106P-25. http://www.rapidtest.com. Calabasas, CA 91302

7. Biosafety in microbiological and biomedical laboratories. 2nd Ed., Washington, DC: CDC/NIH Guidelines, 1988.

8. Bianchi PG, Ardizzone S, Petrillo M, Caruso I, Montrone F. Endoscopio assessment of the effects of metamizol in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adults volunteers. Digestion 1996;57:186-90.

9. Vargas Correa JB, Canto Solis A, Arcila Herrera H. Evaluación del riesgo para agranulocitosis y anemia aplástica. Med Int Mex 1999;5(1):6-10.

10. Consenso sobre eficacia y seguridad del Metamizol. Gac Med Mex 2004;140(1):99-102.

11. International Aplastic Anemia and Agranulocitosis Study (IAAAS). Am Med Assoc 1986;256:1749-57.

12. Peñuelas Acuña J, Oriol L. Metamizol vs ketorolaco en período postquirúrgico. Arch Cirug 2003;71(1):50-54.

13. Planas ME, Gay-Escoda C, Bagan JB, et al. Oral metamizol (1 g and 2 g) versus Ibuprofen and placebo in the treatment of lower third molar surgery pain: randomised doble blind multi-centre study. Eur J Clin Pharmacol 1998;53(6):405-9.

14. Tolman KG. Hepatoxicity of non-narcotic analgesics. Am J Med 1998;105:13S-19S.